Sumitomo Chemical India Ltd

Sumitomo Chemical India Limited (SUMICHEM) reported Q2 and H1 FY27 results, highlighting challenges from erratic monsoons and lower agrochemical consumption. Revenue for Q2 was INR907 crores, down 2% YoY, while H1 revenue was INR1,971 crores, down 1% YoY. Despite industry volume declines, SCIL maintained stable revenue and EBITDA margins near historical levels. Domestic sales grew 2% in Q2, while exports fell 23% due to inventory liquidation. Key products like Flumioxazin and Topgrain saw growth, with Topgrain being the first global launch of a patented biostimulant. The company emphasized its 'Good to Great' transformation, focusing on operational efficiency, technology, and cross-functional collaboration. Capex projects at Dahej and Tarapur aim to expand domestic production, with commercialization expected by FY28. Management noted uncertainties around semiconductor opportunities and discussed potential glyphosate market gains due to regulatory changes. The balance sheet remained strong with INR2,523 crores in cash, and inventory management efforts were underway to normalize levels. Strategic discussions on new product launches and diversification were ongoing, with a focus on agrochemicals and related sectors.

The summary reflects the company's factual reporting on performance, challenges, and strategic initiatives without overtly positive or negative language.